Table 1 Representative clinical trials of microbiota-linked for cancer
From: The microbiota and microbiome in pancreatic cancer: more influential than expected
Category | Clinical Trial ID | Therapeutic Agents/Intervention | Study Phase | Status | Treatment Setting | Primary Outcomes |
|---|---|---|---|---|---|---|
Oral Microbiome and Pancreatic Cancer | NCT03302637 | Specimen Collection | Observational | Completed | Pancreatic Cancer | Compare bacterial taxa |
Treatment of Patients with Cancer with Genetically Modified Salmonella Typhimurium Bacteria | NCT00004988 | VNP20009 | I | Completed | Various Types | Anti-tumor effect; maximum tolerated dose |
Mixed Bacteria Vaccine (MBV) in Patients with Tumors Expressing NY-ESO-1 Antigen | NCT00623831 | Bacterial Vaccine | I | Completed | Various Types | Safety; pyrogenicity; immune responses; overall response |
Probiotics in Colorectal Cancer Patients | NCT00936572 | Probiotics | II | Completed | Colorectal Cancer | Efficacy; immune response |
Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer | NCT03072641 | Probiotics | NA | Completed | Colon Cancer | Microbiota composition and epigenetic changes |
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants with mCRPC | NCT02625857 | JNJ-64041809 | I | Completed | Prostate Cancer | Safety and toxicity; ORR; PFS |
Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With NSCLC | NCT02592967 | JNJ-64041757 | I | Active, not recruiting | NSCLC | Safety and toxicity; ORR; PFS |
Effects of Chemotherapy on Intestinal Bacteria in Patients with Newly Diagnosed Breast Cancer | NCT02370277 | Specimen Collection | Observational | Active, not recruiting | Breast Cancer | Change in intestinal microbiota |
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumor | NCT01562626 | APS001F | I/II | Recruiting | Solid Tumor | Safety and toxicity |
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | NCT03435952 | Pembrolizumab Clostridium NovyiNT | I | Recruiting | Solid Tumor | Maximum tolerated dose; overall response |
Engineering Gut Microbiome to Target Breast Cancer | NCT03358511 | Probiotics | NA | Recruiting | Breast Cancer | Mean number of CD8+ cells |
Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer | NCT02696759 | Specimen Collection | NA | Recruiting | Breast Cancer | pCR |
Microbiome in Lung Cancer and Other Malignancies | NCT03688347 | Specimen Collection | Observational | Recruiting | Lung Cancer | Compare bacterial taxa |
MRx0518 and Pembrolizumab Combination Study | NCT03637803 | MRx0518 Pembrolizumab | I | Not yet recruiting | Solid Tumor | Safety and tolerability; anti-tumor effect |